🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

RecruitingNAAges 18 Years - anyAllInstitut Curie
NCT05558644 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patient with suspicion of localised thymic epithelial tumour. 2. Age ≥ 18 years. 3. Treatment-naïve patient for this disease. 4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers. 5. Signed informed consent form of the patient. Exclusion Criteria: 1. Neoadjuvant chemotherapy. 2. No social security affiliation. 3. Person under legal protection. 4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
💊

What it tests

  • single arm for all patients
📍

Where

3 sites
Institut Curie Paris
Paris, France
Institut Mutualiste Montsouris
Paris, France
Hôpital FOCH
Suresnes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy